IL6 and COVID-19: One of the pathophysiological explanations of this phenomenon lies in the fact that visceral adipose tissue, compared to subcutaneous, secretes 2–3 times higher concentrations of interleukin 6 (35), which is associated with the development of severe forms and fatal outcomes for patients with COVID-19 (1, 7).